The Efficacy of Preemptive Milrinone or Amrinone Therapy in
... a systolic blood pressure between 90 and 130 mm Hg, a cardiac index ⬎2.0 L · min⫺1 · m⫺2, and a pulmonarycapillary wedge pressure ⬍18 mm Hg. For each patient, the total individual doses of dopamine and nitroglycerin administered (in g · kg⫺1 · min⫺1) were recorded, and the mean total dose was calcu ...
... a systolic blood pressure between 90 and 130 mm Hg, a cardiac index ⬎2.0 L · min⫺1 · m⫺2, and a pulmonarycapillary wedge pressure ⬍18 mm Hg. For each patient, the total individual doses of dopamine and nitroglycerin administered (in g · kg⫺1 · min⫺1) were recorded, and the mean total dose was calcu ...
ARDS Network - Critical Care Panama
... Study dates: February 1998 to June 1999. The LARMA study was a randomized, double-blind, placebo-controlled multicenter 2 " 2 factorial study wherein each patient was randomized between lisofylline and placebo. It was designed to test whether the administration of lisofylline early after the onset o ...
... Study dates: February 1998 to June 1999. The LARMA study was a randomized, double-blind, placebo-controlled multicenter 2 " 2 factorial study wherein each patient was randomized between lisofylline and placebo. It was designed to test whether the administration of lisofylline early after the onset o ...
Abdomen Belly, Stomach Abdominal distention
... the agency providing the funds. Research performed under contract is more closely controlled by the agency than research performed under a grant. Disadvantageous, perhaps dangerous; a treatment that should not be used in certain individuals or conditions due to risks. For instance, a drug may be con ...
... the agency providing the funds. Research performed under contract is more closely controlled by the agency than research performed under a grant. Disadvantageous, perhaps dangerous; a treatment that should not be used in certain individuals or conditions due to risks. For instance, a drug may be con ...
Growth Hormone–Releasing Hormone Agonists Reduce Myocardial
... ª 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the ...
... ª 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the ...
as a PDF - City Laser Clinic
... expected much. (Study on effect on wrinkles is yet to be done.) Melasma, is generally considered a contraindication of laser treatment, therefore common techniques such as iontophoresis of bleaching agent, oral administration of tranexamic acid or vitamins C and E, and topical use of bleaching cream ...
... expected much. (Study on effect on wrinkles is yet to be done.) Melasma, is generally considered a contraindication of laser treatment, therefore common techniques such as iontophoresis of bleaching agent, oral administration of tranexamic acid or vitamins C and E, and topical use of bleaching cream ...
A 47 yo male schizophrenic, noted by his mother to be breathing
... Department of Emergency Medicine The Ottawa Hospital ...
... Department of Emergency Medicine The Ottawa Hospital ...
Horacio Kaufmann, Daniela Saadia, Andrei Voustianiouk, David S. Goldstein, Courtney
... decarboxylase inhibitor, carbidopa, on the pressor and NE responses to L-DOPS, a separate 3-day trial was conducted after the double-blind trial (n⫽6; 3 men and 3 women; 2 MSA, 4 PAF; age 63⫾4 years, mean⫾SE). Subjects received L-DOPS alone on day 1, followed by 200 mg of carbidopa alone on day 2 an ...
... decarboxylase inhibitor, carbidopa, on the pressor and NE responses to L-DOPS, a separate 3-day trial was conducted after the double-blind trial (n⫽6; 3 men and 3 women; 2 MSA, 4 PAF; age 63⫾4 years, mean⫾SE). Subjects received L-DOPS alone on day 1, followed by 200 mg of carbidopa alone on day 2 an ...
Chapter 11 – Observational Studies and Experiments
... randomize the order of the runs, not run all the races with the new shoes second. They should blind the athletes by disguising the shoes, if possible, so they don’t know which is which. The experiment could be double blinded, as well, by making sure that the timers don’t know which shoes are being t ...
... randomize the order of the runs, not run all the races with the new shoes second. They should blind the athletes by disguising the shoes, if possible, so they don’t know which is which. The experiment could be double blinded, as well, by making sure that the timers don’t know which shoes are being t ...
Full Text Article
... group.Adverse effects such as mild gastritis, gastric irritation and peripheral flushing were reported with the use of pentoxifylline. Notably, pentoxifylline‟s a safe ...
... group.Adverse effects such as mild gastritis, gastric irritation and peripheral flushing were reported with the use of pentoxifylline. Notably, pentoxifylline‟s a safe ...
![[Type text] Commissioning Framework for Experimental Treatments](http://s1.studyres.com/store/data/010696648_1-84aa01d58679f2e912bbe3e1bfa41d84-300x300.png)
[Type text] Commissioning Framework for Experimental Treatments
... Leeds Clinical Commissioning Groups (CCGs) Leeds North CCG, Leeds South & East CCG and Leeds West CCG Individual Funding Request (IFR) policy sets out the process via which evidence of clinical and cost effectiveness to inform a judgement about an individual funding request is sought. Often there is ...
... Leeds Clinical Commissioning Groups (CCGs) Leeds North CCG, Leeds South & East CCG and Leeds West CCG Individual Funding Request (IFR) policy sets out the process via which evidence of clinical and cost effectiveness to inform a judgement about an individual funding request is sought. Often there is ...
... methacholine had been given. For safety reasons, subjects were given the opportunity to stop the challenge test if they felt too much discomfort. The response was expressed as the percentage fall of FEV1 (∆FEV1) from mean postsaline value, and was plotted against log cumulative dose of inhaled metha ...
Pharmacogenetic testing and Statin Drug Therapy
... KIF6 carriers who take a statin drug have greater reduction in heart attack risk than other people have. Their study found that adjusted 6-month statin adherence was significantly greater in tested patients: 0.77 (95% confidence interval (CI) 0.72-0.82) versus controls 0.68 (95% CI adjusted 0.63-0.7 ...
... KIF6 carriers who take a statin drug have greater reduction in heart attack risk than other people have. Their study found that adjusted 6-month statin adherence was significantly greater in tested patients: 0.77 (95% confidence interval (CI) 0.72-0.82) versus controls 0.68 (95% CI adjusted 0.63-0.7 ...
Template PNT DM/FF002
... Name of Active Ingredients: STU 456 Title of Study: A randomized, parallel, placebo (double blind) and positive (open-label) controlled clinical trial to assess the effect on QT interval as well as overall cardiovascular safety of STU 456 administered by inhalation in healthy volunteers Investigator ...
... Name of Active Ingredients: STU 456 Title of Study: A randomized, parallel, placebo (double blind) and positive (open-label) controlled clinical trial to assess the effect on QT interval as well as overall cardiovascular safety of STU 456 administered by inhalation in healthy volunteers Investigator ...
19 Diel Bondronat
... Equivalent bone marker efficacy to zoledronic acid Favorable safety profile Well tolerated for up to 4 years of treatment No renal safety concerns, even with loading-dose Loading-dose Bondronat . . . it works! Try it and see for yourself ...
... Equivalent bone marker efficacy to zoledronic acid Favorable safety profile Well tolerated for up to 4 years of treatment No renal safety concerns, even with loading-dose Loading-dose Bondronat . . . it works! Try it and see for yourself ...
Ferric Carboxymaltose Prevents Recurrence of
... efficacy end points were analyzed by descriptive statistics comprising mean and standard deviation and with analysis of covariance models. Categoric end points were analyzed by logistic regression. Missing data were treated as missing and only observed cases were used for analysis. Data were analyze ...
... efficacy end points were analyzed by descriptive statistics comprising mean and standard deviation and with analysis of covariance models. Categoric end points were analyzed by logistic regression. Missing data were treated as missing and only observed cases were used for analysis. Data were analyze ...
A randomised phase II study evaluating the efficacy and safety of
... The study was powered to detect a difference in the proportion of patients achieving an ACR20 response at week 28 in the combined ustekinumab group and the combined guselkumab group compared with placebo. Combining the two dose groups of ustekinumab and guselkumab was prespecified to increase the pow ...
... The study was powered to detect a difference in the proportion of patients achieving an ACR20 response at week 28 in the combined ustekinumab group and the combined guselkumab group compared with placebo. Combining the two dose groups of ustekinumab and guselkumab was prespecified to increase the pow ...
PDF Printable version - Meniett - the Australia and New Zealand
... cost impact. Current fees for endolymphatic sac surgery (MBS item 41590) are $992.40 and for Vestibular Nerve Section are $1,293.55 and $1,445.65 (MBS item numbers 41593 and 41596). The cost of using the Meniett™ would also include the cost of inserting a grommet, which currently costs $198.50 per p ...
... cost impact. Current fees for endolymphatic sac surgery (MBS item 41590) are $992.40 and for Vestibular Nerve Section are $1,293.55 and $1,445.65 (MBS item numbers 41593 and 41596). The cost of using the Meniett™ would also include the cost of inserting a grommet, which currently costs $198.50 per p ...
Adaptive Clinical Trial Designs for Simultaneous Testing of Matched
... Application of the original adaptive signature paradigm to a real clinical development setting has many complexities, which will be illustrated here for castration-resistant prostate cancer (CRPC), the advanced, lethal form of the disease. Molecular profiling studies show that reactivation of androg ...
... Application of the original adaptive signature paradigm to a real clinical development setting has many complexities, which will be illustrated here for castration-resistant prostate cancer (CRPC), the advanced, lethal form of the disease. Molecular profiling studies show that reactivation of androg ...
Stem Cells: Treating a Broken Heart
... with patients randomized to receive either an injection of 0.5 million, 1.6 million or 5.0 million cultured adult mesenchymal stem cells (CardioStem) per kilogram of body weight, or placebo. Along with the treatment or placebo, all patients will receive standard treatment, including techniques to ma ...
... with patients randomized to receive either an injection of 0.5 million, 1.6 million or 5.0 million cultured adult mesenchymal stem cells (CardioStem) per kilogram of body weight, or placebo. Along with the treatment or placebo, all patients will receive standard treatment, including techniques to ma ...
A Placebo-Controlled, Randomized Trial of Mesenchymal Stem
... population had relatively advanced disease with 66.1% of patients being categorized as having severe COPD at study entry and an average smoking history of 57.1 pack-years. All patients had at least one clinically significant comorbid condition. Patients in the two treatment groups were relatively we ...
... population had relatively advanced disease with 66.1% of patients being categorized as having severe COPD at study entry and an average smoking history of 57.1 pack-years. All patients had at least one clinically significant comorbid condition. Patients in the two treatment groups were relatively we ...
Original contribution
... While osteopathic manipulative treatment (OMT) is thought to be beneficial for patients with pneumonia, there have been few clinical trials—especially in the elderly. The authors’ pilot study suggested that duration of intravenous antibiotic use and length of hospital stay were promising measures of ...
... While osteopathic manipulative treatment (OMT) is thought to be beneficial for patients with pneumonia, there have been few clinical trials—especially in the elderly. The authors’ pilot study suggested that duration of intravenous antibiotic use and length of hospital stay were promising measures of ...
Document
... • AR information will only be collected on CRFs for a limited number of patients. • Once this information has been collected sites will be ...
... • AR information will only be collected on CRFs for a limited number of patients. • Once this information has been collected sites will be ...
this Report (PDF 1.50 MB)
... tolerability, and clinical responsiveness of MN-166 when administered as an adjunct to riluzole, the only U.S. FDA approved ALS treatment. Patients in the study will be randomized 2:1 to receive either MN-166 or placebo in conjunction with riluzole over a six-month time course. As of February 2015 t ...
... tolerability, and clinical responsiveness of MN-166 when administered as an adjunct to riluzole, the only U.S. FDA approved ALS treatment. Patients in the study will be randomized 2:1 to receive either MN-166 or placebo in conjunction with riluzole over a six-month time course. As of February 2015 t ...
Efficacy and Safety of Drotaverine Hydrochloride
... Design: Double blind, randomized placebo-controlled trial. Setting: Pediatric Gastroenterology clinic of a teaching hospital. Participants: 132 children (age 4-12 y) with recurrent abdominal pain (Apley Criteria) randomized to receivedrotaverine (n=66) or placebo (n=66) orally. Intervention: Childre ...
... Design: Double blind, randomized placebo-controlled trial. Setting: Pediatric Gastroenterology clinic of a teaching hospital. Participants: 132 children (age 4-12 y) with recurrent abdominal pain (Apley Criteria) randomized to receivedrotaverine (n=66) or placebo (n=66) orally. Intervention: Childre ...
Placebo-controlled study
Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham ""placebo"" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment. Often, there is also a further ""natural history"" group that does not receive any treatment at all.The purpose of the placebo group is to account for the placebo effect, that is, effects from treatment that do not depend on the treatment itself. Such factors include knowing one is receiving a treatment, attention from health care professionals, and the expectations of a treatment's effectiveness by those running the research study. Without a placebo group to compare against, it is not possible to know whether the treatment itself had any effect.Patients frequently show improvement even when given a sham or ""fake"" treatment. Such intentionally inert placebo treatments can take many forms, such as a pill containing only sugar, a surgery where nothing efficacious is actually done (just an incision and sometimes some minor touching or handling of the underlying structures), or a medical device (such as an ultrasound machine) that is not actually turned on. Also, due to the body's natural healing ability and statistical effects such as regression to the mean, many patients will get better even when given no treatment at all. Thus, the relevant question when assessing a treatment is not ""does the treatment work?"" but ""does the treatment work better than a placebo treatment, or no treatment at all?"" As one early clinical trial researcher wrote, ""the first object of a therapeutic trial is to discover whether the patients who receive the treatment under investigation are cured more rapidly, more completely or more frequently, than they would have been without it.""p.195 More broadly, the aim of a clinical trial is to determine what treatments, delivered in what circumstances, to which patients, in what conditions, are the most effective.Therefore, the use of placebos is a standard control component of most clinical trials, which attempt to make some sort of quantitative assessment of the efficacy of medicinal drugs or treatments. Such a test or clinical trial is called a placebo-controlled study, and its control is of the negative type. A study whose control is a previously tested treatment, rather than no treatment, is called a positive-control study, because its control is of the positive type.Government regulatory agencies approve new drugs only after tests establish not only that patients respond to them, but also that their effect is greater than that of a placebo (by way of affecting more patients, by affecting responders more strongly, or both). As a result, ""placebo-controlled studies often are designed in such a way that disadvantages the placebo condition"".